Shionogi aims to double flu-drug market with FDA-approved treatment
Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.
No comments:
Post a Comment